JAZZ

NEUTRALEarnings

Jazz Pharmaceuticals plc

2026-02-25

Price

$196.83

+13.23%

Score11.2Priority

Signals4/8 DNA3/13 Act · 1/4 Risk

SentimentNEUTRALScore: 9

Volume5.4xvs 20d avg

Analysis

JAZZ is executing a high-conviction 'Earnings Breakout' following its Q4 2025 report released yesterday, where it delivered a double-beat on Revenue ($1.2B, +10% YoY) and Adjusted EPS ($6.64). The move is structurally supported by accelerating commercial execution in its core neuroscience franchise (Xywav +16%) and the blockbuster status of Epidiolex, alongside pipeline optimism for its newly approved oncology asset, Ziihera. In the current RISK_ON (EARNINGS) regime, the market is aggressively rewarding this operational efficiency and ignoring slightly mixed 2026 guidance, viewing the 5.4x volume surge as a signal of institutional repricing and accumulation.

Fired Signals

ALPHA MALESTEADY CLIMBGOLDEN CROSSPERFECT STACKBREAKOUTINSIDE OUTBREAKAWAY GAPWEAK FINISH

Key Takeaways

**Thesis:** Structural repricing driven by a Q4 earnings beat and strong launch metrics for new assets (Modeyso), validating the pivot beyond legacy Xyrem.
**Catalyst:** Q4 Earnings Beat (Rev $1.2B vs $1.16B est) + Analyst Upgrades (BofA to $275, TD Cowen to $220).
**Risk:** Invalidation of the breakout if price fails to hold above the $183 prior resistance level, suggesting a 'gap and crap' rather than a sustained trend.

← Back to 2026-02-25 View Full JAZZ History →Yahoo Finance &nearr;